SUTRO BIOPHARMA, INC.
STRONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for STRO. That does not mean none is planned.
Get an email about STRO's next catalysts
Track SUTRO BIOPHARMA (STRO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Website| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
STRO-002 | Phase 2 | Neoplasm Malignant | - | - |
Frequently asked questions
What is in SUTRO BIOPHARMA, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in SUTRO BIOPHARMA, INC.'s (STRO) pipeline across Phase 2. Its lead program is STRO-002 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SUTRO BIOPHARMA, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for SUTRO BIOPHARMA, INC. (STRO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track STRO biotech catalysts?→
Add STRO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SUTRO BIOPHARMA, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.